Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is experiencing a surge in prescriptions for its Alzheimer's disease medication, AUVELITY, as the drug gains traction in the market. Weekly new-to-brand prescriptions for AUVELITY reached a record 3,800, with Alzheimer's disease agitation becoming the fastest-growing segment of the drug's usage.
Patients aged 65 and older now account for approximately 31% of new-to-brand prescriptions, up from around 19% before the indication's approval. Axsome Therapeutics reiterated its $8 billion long-term peak-sales outlook for AUVELITY, with an even split between major depressive disorder and Alzheimer's disease agitation. The company expects operating expenses to remain stable in the second half of the year while revenue grows faster, potentially leading to profitability.
Brief written by urgent.news from Yahoo Finance's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
